.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ACCORD glycemia trial tested whether targeting near-normal HbA1c in patients with type 2 diabetes at high cardiovascular risk would reduce major cardiovascular events. Intensive therapy lowered HbA1c more substantially than standard treatment, but the trial was stopped early because all-cause mortality was higher in the intensive-treatment group. The finding remains a foundational lesson in diabetes care: aggressive glucose lowering is not automatically associated with better survival, particularly in older, high-risk patients with long-standing disease and multiple comorbidities. For internists, treatment goals should therefore be individualized according to duration of diabetes, hypoglycemia risk, cardiovascular disease, kidney function, frailty and life expectancy. Modern therapies with demonstrated cardiovascular and renal benefits have also changed the therapeutic landscape since ACCORD. The study should be interpreted in its historical context while retaining its central clinical lesson—more intensive treatment is not necessarily better when the harms of polypharmacy and hypoglycemia outweigh incremental glycemic benefit.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ACCORD glycemia trial tested whether targeting near-normal HbA1c in patients with type 2 diabetes at high cardiovascular risk would reduce major cardiovascular events. Intensive therapy lowered HbA1c more substantially than standard treatment, but the trial was stopped early because all-cause mortality was higher in the intensive-treatment group. The finding remains a foundational lesson in diabetes care: aggressive glucose lowering is not automatically associated with better survival, particularly in older, high-risk patients with long-standing disease and multiple comorbidities. For internists, treatment goals should therefore be individualized according to duration of diabetes, hypoglycemia risk, cardiovascular disease, kidney function, frailty and life expectancy. Modern therapies with demonstrated cardiovascular and renal benefits have also changed the therapeutic landscape since ACCORD. The study should be interpreted in its historical context while retaining its central clinical lesson—more intensive treatment is not necessarily better when the harms of polypharmacy and hypoglycemia outweigh incremental glycemic benefit.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
